Background: Prostate cancer ranks as the second most common cancer in men worldwide. Dose escalation to the tumor and/or the prostate improves biochemical recurrence-free survival. However, interobserver variability in lesion contouring poses a significant limitation to such therapeutic approaches.
View Article and Find Full Text PDF